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 Objective: To report a case of significant morbidity and end-organ 
damage development during Peg-interferon Alpha-2a/Ribavirin therapy. 
Case report: A 27-year-old woman patient with chronic hepatitis C 
diagnosis, genotype1b, Anti HCV positive, and HCV-RNA 6. 05 x 105 
IU/mL, presented to our clinic in order to initiate the approved treatment 
regimen with subcutaneous peginterferon alfa 2a (PEG-INF-a2a, s.c.) plus 
oral ribavirin. There were no evident abnormalities in the patient’s physical 
examination and laboratory data prior to the treatment, except for general 
asthenia and arthralgias and, above normal biliriubin levels plus positive 
smooth muscle antibodies (SMA). The patient was started on 180 mcg PEG 
interferon alpha-2a s. c. once a week with ribavirin 1000 mg/day. Four 
months later, despite undetectable HCV-RNA, she developed anemia, 
neutropenia, thrombocytopenia, and high transaminase levels, due to which 
the staff opted for a half-dose of Peg-interferon Alpha-2a/Ribavirin. After 
that, she suffered deterioration in liver function (Child class C, MELD score 
= 23.4) in association with non-invasive predictors of liver fibrosis, and with 
common radiologic changes of liver cirrhosis. 
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Conclusion: Patients with preexisting auto antibodies and chronic hepatitis 
C, especially women, may be predisposed to autoimmune hepatitis during 
interferon and ribavirin therapy. These patients require careful monitoring if 
IFN is considered as first line treatment. 
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Introduction 
 Intereferon alpha (IFN-a) monotherapy was the first approved 
treatment for chronic hepatitis. As cited in Fried at. al., 2002, results of 
randomized, controlled trials subsequently indicated that the addition of 
ribavirin (Rbv) to IFN-a produces improved sustained virologic response 
rates (SVR). However, due to treatment-related adverse effects, combination 
therapy significantly increased the risk of dose modifications and 
discontinuations and, as has been observed clinically, dose modifications 
appeared to be less than optimal for HCV eradication. 19-22% of patients 
treated with Peginterferon alfa-2a and ribavirin, required reduction of 
ribavirin dose during therapy (Hadzyannis, 2002). 
 Side effects of IFN-a, Rbv, and IFN-a/Rbv combination therapy 
include depression, persistent fatigue, transient flulike symptoms (headache, 
fatigue, myalgia, chills, and fever), and bone marrow suppression leading to 
anemia and neutropenia (Maddrey,1999). 
 Other authors,  as Karim et al. (2001), Boonyapisit et al. (2002), Li 
SD et al. (2002), Teragawa et al. (1996), Wesche et. al. (2001),  reported that 
treatment with standard interferon with or without ribavirin may be 
associated with more specific and serious adverse events, with the potential 
to cause significant morbidity and end-organ damage, like hearing loss, 
retinopathy, acute renal failure, congestive heart failure and, according to 
Dalekos et al. (1999), induction or exacerbation of autoimmune diseases. 
 Patients with documented hepatitis C infection may deteriorate 
during IFN treatment if an underlying autoimmune hepatitis is present. This 
has been observed particularly in individuals with LKM positive antibody 
(Todros, Saracco, Durazzo, et al. 1995). Even though IFN seems to be safe in 
most HCV/anti - LKM-1 positive patients, these patients require careful 
monitoring if IFN is considered as first line treatment therapy. On the other 
hand, previously, it has been showed that INF therapy should be stopped due 
to occurrence or exacerbation of autoimmune phenomenon (Okanoue T, 
Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. 1996). 
 Hereby, we present a case of a female patient with preexisting auto 
antibodies and chronic hepatitis C who developed significant morbidity and 
liver failure during Peg-interferon Alpha-2a/Ribavirin therapy. 




 A 27-year-old woman, presented in January 2014 at University Clinic 
of Gastrohepatology, University Hospital Center “Mother Teresa” in Tirana, 
Albania, with the diagnosis of chronic hepatitis C. She presented to our clinic 
in order to initiate the approved treatment regimen with subcutaneous PEG-
INF-alfa2a plus oral ribavirin. She was carrier of hepatitis C virus genotipe 
1b, and HCV-RNA was 6. 05 x 105 IU/ml, as determined by Cobas 
AmpliPrep/TaqMan HCV test.   
 She did not smoke, drink alcohol, or use drugs. She weighed 69 kg, 
and was on a semi-vegetarian diet, excluding grapefruits. There was a history 
of two cesarean section deliveries. There were no evident abnormalities in 
the patient’s physical examination prior to the treatment. The skin was pale 
and the abdomen was soft and nontender, with no organomegaly.  
 At the initial visit, the results of laboratory tests, including complete 
blood count, electrolytes, and albumin were normal, as were the results of 
coagulation test and renal function. Transaminase levels, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin level 
showed a slight elevation. Immunological test showed the titer of smooth 
muscle antibodies (SMA) 1:40. The other results of laboratory tests are 
shown in table 1. Also, according to Schiavon at. al. (2014), we evaluated the 
non-invasive serum fibrosis markers such as fibrosis-4 score based on age, 
ALT, AST and platelet count (FIB-4), AST to platelet ratio index (APRI), 
platelet count to spleen diameter (PC/SD), AST-to-ALT ratio (AST/ALT), 
and age-spleen-to-platelet ratio index (ASPRI) before initiating treatment 
with INF, and during follow-up (table 2). The treatment to the patient was 
started on 180 mcg PEG interferon alpha-2a s. c. once a week with ribavirin 
1000 mg/day orally in 2 divided doses. 
 After three months, on March 2014, there was no detectable HCV-
RNA. Two months later, on May 2014, the patient was not feeling well, 
complaining of a persistent fatigue and generalized malaise. Laboratory 
results showed deterioration of hematologic indices and transaminase values. 
Due to the anemia, neutropenia, thrombocytopenia, and high transaminase 
levels, the medical staff decided to continue the treatment with half-dose of 
PEG interferon alpha-2a/ribavirin (90 mcg PEG interferon once a week with 
500 mg/day ribavirin). 
 On June 2014, she re-admitted in our clinic for closer monitoring, 
because despite having the treatment dose, the patient felt continuously tired. 
The physical examination revealed hepatosplenomegaly and jaundice on 
bulbar conjunctiva and skin, with no spider angiomas or palmar erythemas. 
The platelet, erythrocyte and leukocyte count continued to decline (101x103 
cells/µl, 2.87x106cells/mm3 and 3.6x103 cells/µl, respectively), hemoglobin 
level dropped to 6.8g/dL and bilirubin, and transaminase levels continued to 
European Scientific Journal June 2015 edition vol.11, No.18  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
106 
rise (bilirubin level to 2.8mg/dL, AST to 612 U/L, ALT to 311U/L). Also, 
the noninvasive biomarkers of fibrosis were worse than before (table 2), so 
the interferon therapy was interrupted. HCV-RNA level remained 
undetectable even after the treatment interruption. However, the bilirubin 
level continued to rise (to 11.1mg/dL), serum gamma globulin reached its 
peak (3.23g/dl), and noninvasive biomarkers were further worsened (tabel 2). 
Also, after the termination of INF therapy, the prognostic markers of 
cirrhosis continued to worsen (Child class C and MELD score=23.4). 
Furthermore, the total score of autoimmune hepatitis (AIH) revised in 1999, 
was increased to 11 (probable AIH) (table 2). The abdominal ultrasound 
examination showed enlargement of liver with macronodular parenchyma 
and abnormalities in its contour; there were ascites in abdominal cavity, and 
splenomegaly. 
 The patient was discharged from hospital at the request of the family 
members with the diagnosis of decompensated liver cirrhosis, with biological 
activity and severe liver failure, and with intrahepatic cholestasis. She went 
to Italy with the hope to be included in a liver transplant list. 
 
Discussion 
 Chapman, Stace, Edgar, et al. (2001), concluded that PEG -IFN-
alfa2a/Rbv treatment (180 mcg of PEG-IFN-alfa2a once weekly s.c. and 
1000–1200 mg/day oral Rbv) resulted in an overall much better SVR rate 
than PEG-IFN-alfa2a alone. In addition, Moreno-Monteagudo, Castro, De 
Pedro, et al. (2002), suggested that that IFN-alfa/Rbv combination therapy is 
effective for patients who experience relapse or do not respond to IFN-alfa 
monotherapy. Combination therapy also produces a greater reduction in liver 
fibrosis than does IFN-alfa monotherapy. 
 However, the adverse effects of HCV treatment may compromise the 
success of therapy. Anemia has been found to be more pronounced with 
combination therapy than with IFN-a monotherapy.  The results from a large 
population treated with combination Peginterferon alfa-2a and ribavirin 
(Hadzyannis, 2002) have showed that 19-22% of patients required reduction 
of ribavirin dose during therapy. This was somewhat more than patients 
requiring dose reduction in the trial with peginterferon alfa-2b/ribavirin (12-
13%). In addition, dose reductions due to neutropenia and thrombocytopenia 
were more common in association with PEG-IFN-alfa/Rbv therapy than with 
standard IFN-alfa/Rbv therapy. High incidence of neutropenia and 
thrombocytopenia associated with PEG-IFN-a may be due to the longer bone 
marrow exposure, because of longer half-life of the agent; however, the 
recommended weekly dosages for combination therapy of both formulations 
of PEG-IFN-alfa (1.5 mg/kg of PEG-IFN-alfa2b once weekly and 180 mg of 
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PEG-IFN-alfa2a once weekly) are also greater than the recommended 
weekly dose of IFN-alfa (3 million IU of IFN-alfa2b 3 times/week).  
 IFN-alfa/Rbv treatment–induced anemia has been called a “mixed” 
anemia, because the effects of both drugs contribute to its etiology. Van 
Vlierbergh et al. (2001) found out that the major side effect of treatment with 
Rbv is hemolytic anemia. At Rbv doses of 800 mg/day, Rbv-induced 
hemolytic anemia causes a dramatic reduction in hemoglobin levels (of 2–3 
g/dL), usually 4 weeks of initiation of treatment. When combination therapy 
with IFN-a/Rbv is used, 25%–30 % of patients develop hemoglobin levels 
<11g/dL. In addition to hemolysis Cacoub, Poynard, Ghillani, Charlotte, 
Olivi, Piette, et al., stated that Rbv induced anemia can occur by various 
mechanisms, including suppression of hematopoietic progenitor cell 
proliferation, activation of programmed cell death (apoptosis) in erythroid 
progenitor cells, provocation of immune hemolysis, and impairment of renal 
function. 
 Hepatitis C virus (HCV) is associated with different autoimmune 
manifestations. Based on different studies, 40-74% of HCV infected patients 
may experience other complications during the course of the disease that are 
principally immunological.  The prevalence of HCV infection is much higher 
among some of these conditions and suggests a pathogenetic role of the 
virus. HCV is a trigger for the autoimmune reactions resulting in production 
of autoantibodies.  
 In recent years, Cacoub et al. found positive antinuclear antibodies in 
41% of patients, rheumatoid factor in 38%, anticardiolipin antibodies in 
27%, and antithyroglobulin antibodies in 13% of patients. Some of these 
antibodies such as anti-C-reactive protein correlated with the severity of liver 
disease. Papo, Marcellin, Bernuau, et al. (1992) underlined that in chronic 
liver disease anti-HCV high seropositivity may also point to autoimmune 
processes. Molecular mimicry of amino acid sequences of the hepatitis C 
virus with the human cytochromes and cellular structures may contribute to 
virus-triggered autoimmunity. There is a striking prevalence of autoimmune 
phenomena in patients who express circulating cryoglobulins, rheumatoid 
factor and nonspecific autoantibodies such as, smooth muscle antibodies, 
liver kidney microsomal (LKM)-1 antibodies, antinuclear antibodies,  and 
antithyroid antibodies. Shindo, Di Bisceglie, Hoofnagle (1992) stated that 
autoimmune hepatitis can develop during treatment of chronic hepatitis B 
and C with interferon. Although generally considered to be rare, in one 
report of 144 patients with hepatitis C, deterioration in liver function and the 
development of autoantibodies occurred in seven percent during interferon 
therapy, all of whom were women. Sezaki, Arase, Tsubota, et al. (2003), 
demonstrated that some of these patients had preexisting autoantibodies, 
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 Even though infrequently reported (<1%), one of the most serious 
adverse events associated with standard interferon therapy, is induction or 
exacerbation of autoimmune diseases. In this case, we came to the 
conclusion that the patient developed an autoimmune hepatitis, with 
deterioration in liver function. Patients with preexisting autoantibodies and 
chronic hepatitis C, especially women, may be predisposed to autoimmune 
hepatitis during interferon and ribavirin therapy. These patients require 
careful monitoring if IFN is considered as first line treatment. Further 
investigations are warranted to consider re-administration of interferon at 
low dose or interferon free therapy in chronic hepatitis C virus infection with 
preexisting autoimmune phenomenon.  
 
References: 
www.scliver.com A recent study by Fried et al. shows that full dose 
scheduling of both PEG-interferon and ribavirin permits 75 % of early 
virologic responders to have an ultimate SVR. 
Hadzyannis SJ. Peginterferon alfa-2a (40 KD) in combination with ribavirin 
(RBV): Efficacy and safety from a phase III, randomized, double-blind, 
multicenter study examining effect of duration and RBV dose (Abstract 
536). European Association for the Study of the Liver (EASL) 2002. 
Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in 
chronic hepatitis C–relapsed and treatment-naıve patients. Semin Liver Dis 
1999; 19 (Suppl 1):67–75.  
Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis 
in a patient treated with alpha-interferon and ribavirin for hepatitis C 
infection. Am J Med Sci 2001; 322:233-235. 
Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated 
vasculitic neuropathy following treatment with interferon alpha: a case report 
and literature review. Muscle Nerve 2002; 25:909-913. 
Li SD, Yong S, Srinivas D, Van T. Reactivation of sarcoidosis during 
interferon therapy. J Gastroenterol 2002; 37:50-54. 
Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of 
interferon on the cardiovascular system in patients with chronic hepatitis C. 
Jpn Heart J 1996;37:905-915. 
Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the 
adrenal cortex and pancreatic islet cells by interferon alpha therapy for 
chronic hepatitis C. Gut 2001; 48:378–83. 
European Scientific Journal June 2015 edition vol.11, No.18  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
109 
Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of 
cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during 
alpha-interferon treatment. J Hepatol 1999; 30:366–75. 
Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa 
therapy in chronic hepatitis C with autoantibodies to liver-kidney 
microsomes. Hepatology 1995; 22:1374–8. 
Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. 
Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 
1996; 25:283–91. 
Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive 
diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 
2014; 20(11): 2854-2866). 
Chapman BA, Stace NH, Edgar CL, et al. Interferon-alpha2a/ribavirin versus 
interferon-alpha2a alone for the retreatment of hepatitis C patients who 
relapse after a standard course of interferon. N Z Med J 2001; 114:103–4. 
Moreno-Monteagudo JA, Castro A, De Pedro A, et al. Interferon-alpha plus 
ribavirin for 12 months increases the sustained response rates in chronic 
hepatitis C relapsers. Aliment Pharmacol Ther 2002; 16:243–9. 
Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors 
influencing ribavirin-induced hemolysis. BASL Steering Committee. J 
Hepatol 2001; 34:911–6. 
Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. 
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. 
Multidepartment Virus C. Arthritis Rheum 1999; 42(10):2204-12.  
Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis 
exacerbated by alpha-interferon. Ann Intern Med 1992; 116:51.  
Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver 
disease during interferon alfa therapy for chronic hepatitis C. 
Gastroenterology 1992; 102:1406.  
Sezaki H, Arase Y, Tsubota A, et al. Type C-chronic hepatitis patients who 
had autoimmune phenomenon and developed jaundice during interferon 




European Scientific Journal June 2015 edition vol.11, No.18  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
110 
Table 1. Patient’s laboratory data at the initiation of INF therapy 
Variables Value Normal range 
Blood chemistry   
ALT (U/L) 131 0 – 45 
AST (U/L) 102 0 – 35 
GGT (U/L) 38 0 – 55 
Total bilirubin (mg/dL) 2.5 0.3 – 1.2 
Direct bilirubin (mg/dL) 1.6 0.0 – 0.2 
ALP (U/L) 55 30 –120 
Glucose (mg/dL) 98 74 –106 
Urea ( mg/dL) 20 10 – 43 
Creatinine (mg/dL) 0.6 0.6 – 1.2 
CRP (mg/L) 2.15 1.10 – 8.00 
Total protein (g/dL) 7. 2 6.0 – 8.3 
Albumin (g/dL) 4.6 3.5 – 4.2 
Alpha 1 globulin (%) 4. 4 2. 9 – 4. 9 
Alpha 2 globulin (%) 9. 8 7. 1 – 11. 8 
Beta 1 globulin (%) 6. 2 4. 7 – 7. 2 
Beta 2 globulin (%) 4. 8 3. 2 – 6. 5 
Gamma globulin (%) 14. 2 11. 1 – 18. 8 
Sodium (mmol/L) 132 136 – 146 
Chloride (mmol/L) 104 98 – 106 
Potassium (mmol/L) 3.9 3.4 – 4.5 
Cholesterol (mg/dL) 121 120 – 220 
Triglyceride (mg/dL) 71 50 – 150 
Viral markers   
HCV-RNA level 
(IU/mL) 6. 05 x 10
5 - 
Virus genotype 1b - 
Anti HCV Positive - 
HBsAg Negative - 
HBcAb Negative - 
Hematology   
RBC (x106 cells/mm3) 4. 66 3.80 – 5.80 
Hemoglobin  (g/dL) 14.2 11.0 – 16.5 
WBC (x103 cells/µl) 7. 1 3.5 – 10.0 
Platelet count (x103 
cells/µl) 221 
150 – 390 
Coagulation test   
International Normalized 
Ratio (INR) 1.15 
0.850 – 1.200 
APTT (sec) 32.2 25 – 35 
Immunology   
Anti mitochondrial 
antibodies (AMA) Negative 
- 
Smooth muscle 
antibodies (SMA) 1:40 
- 
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Table 2. Clinical course, non-invasive biomarkers and AIH scoring system before, during, 
and after treatment with INF 





HCV-RNA (IU/mL) 6. 05 x 105 No detectable No detectable 
Clinical course    
Fatigue Yes Yes Yes 
Fever No No No 
Abdominal pain No Yes Yes 
Jaundice No Yes Yes 
Pruritus No Yes Yes 
Ascites No Yes Yes 
Encephalopathy No No No 
AIH scoring system    
Female sex +2 +2 +2 
ALP/AST +2 +2 +2 
Gamma globulin g/dl 0 0 +3 
Anti mitochondrial antibodies 
(AMA) +3 +3 +3 
Smooth muscle antibodies 
(SMA) +1 +1 +1 
Hepatitis viral markers -3 -3 -3 
Drug history +1 +1 +1 
Alcohol intake +2 +2 +2 
Other AI diseases - - - 
Other additional parameters - - - 
Total score 8 8 11 
Prognostic markers    
Child-Pugh class A B C 
MELD score 11.5 12.8 23.4 
Non-invasive biomarkers    
FIB-4 score 1.09 11.59 10.72 
APRI 1.03 16.82 16.76 
ASPRI 4.97 13.41 15.84 
AST/ALT 0.77 2.01 2.11 
PL/SD 2009.1 585.7 631.2 
 
APRI, AST to platelet ratio index; ASPRI, age–spleen-to-platelet ratio index; AST/ALT, 
AST-to-ALT ratio; FIB-4, fibrosis-4 score based on age, ALT, AST and platelet count; 
MELD, Model for End-stage Liver Disease; PC/SD, platelet count to spleen diameter. 
  
